Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaptanib for diabetic macular edema retinal functional and morphologic changes
2009-014444-11Phase 3Terminated
- Sponsor
- Fondazione G.B. Bietti-IRCCS
- Start
- Nov 2009
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegaptanib sodium in diabetic macular edema (DME), sponsored by Fondazione G.B. Bietti-IRCCS. Primary endpoints: Stabilization and/or improvement of MP1 retinal sensitivity and Stabilization and/or improvement of mfERG retinal sensitivity. Started Nov 2009; status: terminated.
02
Drugs
pegaptanib sodium
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2009-014444-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014444-11.